{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:57:32Z","timestamp":1767146252887,"version":"build-2238731810"},"reference-count":153,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jaad.2021.02.073","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T16:17:29Z","timestamp":1614961049000},"page":"1523-1537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Intraepithelial autoimmune bullous dermatoses disease activity assessment and therapy"],"prefix":"10.1016","volume":"84","author":[{"given":"Carmen M.","family":"Montagnon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia S.","family":"Lehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dedee F.","family":"Murrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Camilleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislav N.","family":"Tolkachjov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2021.02.073_bib1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.clindermatol.2011.03.017","article-title":"Severity score indexes for blistering diseases","volume":"30","author":"Daniel","year":"2012","journal-title":"Clin Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2021.02.073_bib2","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1038\/jid.2009.72","article-title":"Reliability and convergent validity of two outcome instruments for pemphigus","volume":"129","author":"Rosenbach","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.073_bib3","first-page":"CD006263","article-title":"Interventions for pemphigus vulgaris and pemphigus foliaceus","volume":"1","author":"Martin","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.jaad.2021.02.073_bib4","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.073_bib5","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/bjd.14405","article-title":"Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus","volume":"175","author":"Boulard","year":"2016","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.073_bib6","first-page":"4","article-title":"Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus","volume":"17","author":"Pf\u00fctze","year":"2007","journal-title":"Eur J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.073_bib7","first-page":"224","article-title":"Pemphigus vulgaris activity score and assessment of convergent validity","volume":"51","author":"Chams-Davatchi","year":"2013","journal-title":"Acta Med Iran"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.073_bib8","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1001\/jamadermatol.2013.8175","article-title":"Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score","volume":"150","author":"Rahbar","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.073_bib9","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijwd.2016.10.003","article-title":"Validation studies of outcome measures in pemphigus","volume":"2","author":"Hanna","year":"2016","journal-title":"Int J Womens Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.073_bib10","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jdermsci.2013.02.011","article-title":"A higher correlation of the antibody activities against the calcium-dependent epitopes of desmoglein 3 quantified by ethylenediaminetetraacetic acid-treated enzyme-linked immunosorbent assay with clinical disease activities of pemphigus vulgaris","volume":"70","author":"Kamiya","year":"2013","journal-title":"J Dermatol Sci"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.073_bib11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2340\/00015555-1666","article-title":"Clinical significance of anti-desmoglein-1 and -3 circulating autoantibodies in pemphigus patients measured by area index and intensity score","volume":"94","author":"Patsatsi","year":"2014","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"10.1016\/j.jaad.2021.02.073_bib12","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jamadermatol.2013.4972","article-title":"Development of a quality-of-life instrument for autoimmune bullous disease: The Autoimmune Bullous Disease Quality of Life questionnaire","volume":"149","author":"Sebaratnam","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.02.073_bib13","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/bjd.12623","article-title":"The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease","volume":"169","author":"Tjokrowidjaja","year":"2013","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.073_bib14","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.clindermatol.2011.01.013","article-title":"Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis)","volume":"29","author":"Joly","year":"2011","journal-title":"Clin Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.073_bib15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1440-0960.2005.00191.x","article-title":"Comparison of desmoglein ELISA and indirect immunofluorescence using two substrates (monkey oesophagus and normal human skin) in the diagnosis of pemphigus","volume":"46","author":"Ng","year":"2005","journal-title":"Australas J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.073_bib16","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.4049\/jimmunol.159.4.2010","article-title":"Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins","volume":"159","author":"Ishii","year":"1997","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.073_bib17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1046\/j.1365-2133.2002.04838.x","article-title":"Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3","volume":"147","author":"Cheng","year":"2002","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.073_bib18","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: recommendations of an international panel of experts","volume":"82","author":"Murrell","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.02.073_bib19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archdermatol.2009.9","article-title":"ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus","volume":"145","author":"Abasq","year":"2009","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.073_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jid.2018.04.042","article-title":"Large international validation of ABSIS and PDAI pemphigus severity scores","volume":"139","author":"H\u00e9bert","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"10083","key":"10.1016\/j.jaad.2021.02.073_bib21","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomized trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jaad.2021.02.073_bib22","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1001\/jamadermatol.2019.3236","article-title":"Factors associated with complete remission after rituximab therapy for pemphigus","volume":"155","author":"Kushner","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.02.073_bib23","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/jamadermatol.2020.0290","article-title":"Factors associated with short-term relapse in patients with pemphigus who receive rituximab as first-line therapy: a post hoc analysis of a randomized clinical trial","volume":"156","author":"Mignard","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2021.02.073_bib24","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1001\/archderm.142.11.1447","article-title":"A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus","volume":"142","author":"Beissert","year":"2006","journal-title":"Arch Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2021.02.073_bib25","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/j.1468-3083.2007.02286.x","article-title":"An alternate-day corticosteroid regimen for pemphigus vulgaris. A 13-year prospective study","volume":"21","author":"Chaidemenos","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1 Pt 1","key":"10.1016\/j.jaad.2021.02.073_bib26","first-page":"13","article-title":"[Treatment of pemphigus vulgaris by azathioprine and low doses of prednisone (Lever scheme)]","volume":"130","author":"Benoit Corven","year":"2003","journal-title":"Ann Dermatol Venereol"},{"issue":"1 Pt 2","key":"10.1016\/j.jaad.2021.02.073_bib27","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jfma.2019.04.020","article-title":"Maintenance therapy with azathioprine prolonged duration of remission for pemphigus patients who received rituximab as first-line or add-on therapy","volume":"119","author":"Cho","year":"2020","journal-title":"J Formos Med Assoc"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.073_bib28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1610-0378.2005.04747.x","article-title":"Intravenous dexamethasone-cyclophosphamide pulse therapy in comparison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study","volume":"3","author":"Rose","year":"2005","journal-title":"J Dtsch Dermatol Ges"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.073_bib29","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaad.2007.05.024","article-title":"Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris","volume":"57","author":"Chams-Davatchi","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.073_bib30","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/1346-8138.14173","article-title":"Azathioprine monotherapy in autoimmune blistering diseases: a feasible option for mild to moderate cases","volume":"45","author":"Kakuta","year":"2018","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.073_bib31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s13555-019-00346-x","article-title":"A comparison of azathioprine and mycophenolate mofetil as adjuvant drugs in patients with pemphigus: a retrospective cohort study","volume":"10","author":"Sukanjanapong","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.073_bib32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","article-title":"A randomized double-blind trial of intravenous immunoglobulin for pemphigus","volume":"60","author":"Amagai","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.02.073_bib33","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2165\/00128071-200809050-00007","article-title":"Adjuvant high-dose intravenous immunoglobulin therapy can be easily and safely introduced as an alternative treatment in patients with severe pemphigus vulgaris: a retrospective preliminary study","volume":"9","author":"Mignogna","year":"2008","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.02.073_bib34","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1001\/archderm.138.9.1158","article-title":"Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris","volume":"138","author":"Sami","year":"2002","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.073_bib35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1067\/mjd.2002.116338","article-title":"Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy","volume":"46","author":"Ahmed","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.073_bib36","first-page":"174","article-title":"Steroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus","volume":"12","author":"Sami","year":"2002","journal-title":"Eur J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.02.073_bib37","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1067\/mjd.2001.116339","article-title":"Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment","volume":"45","author":"Ahmed","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.02.073_bib38","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2230.2006.02220.x","article-title":"Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption","volume":"31","author":"Shimanovich","year":"2006","journal-title":"Clin Exp Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2021.02.073_bib39","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1610-0387.2008.06605.x","article-title":"Successful therapy of pemphigus vulgaris with immunoadsorption using the TheraSorb adsorber","volume":"6","author":"G\u00fcnther","year":"2008","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.073_bib40","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2133.2011.10585.x","article-title":"Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine\/mycophenolate mofetil: a pilot study of 23 patients","volume":"166","author":"Kasperkiewicz","year":"2012","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2021.02.073_bib41","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1610-0387.2007.06342.x","article-title":"Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases","volume":"5","author":"Zillikens","year":"2007","journal-title":"J Dtsch Dermatol Ges"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.073_bib42","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1365-2133.2009.09590.x","article-title":"Pulsed intravenous cyclophosphamide and methylprednisolone therapy in refractory pemphigus","volume":"162","author":"Saha","year":"2010","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.073_bib43","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00128071-200708020-00004","article-title":"Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris","volume":"8","author":"Olszewska","year":"2007","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.073_bib44","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000057886","article-title":"Long-term efficacy of dexamethasone-cyclophosphamide pulse therapy in pemphigus","volume":"204","author":"Kanwar","year":"2002","journal-title":"Dermatology"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.073_bib45","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.det.2011.06.021","article-title":"Infection and infection prevention in patients treated with immunosuppressive medications for autoimmune bullous disorders","volume":"29","author":"Lehman","year":"2011","journal-title":"Dermatol Clin"},{"issue":"5","key":"10.1016\/j.jaad.2021.02.073_bib46","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jaad.2009.11.588","article-title":"Role of primary prophylaxis for pneumocystis pneumonia in patients treated with systemic corticosteroids or other immunosuppressive agents for immune-mediated dermatologic conditions","volume":"63","author":"Lehman","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2021.02.073_bib47","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/ijd.13231","article-title":"Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions: a systematic review with recommendations for prophylaxis","volume":"55","author":"Gonz\u00e1lez Santiago","year":"2016","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.073_bib48","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jaad.2014.04.040","article-title":"Two decades of using the combination of tetracycline derivatives and niacinamide as steroid-sparing agents in the management of pemphigus: defining a niche for these low toxicity agents","volume":"71","author":"McCarty","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.073_bib49","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1365-4362.1999.00624.x","article-title":"Pemphigus vulgaris: benefits of tetracycline as adjuvant therapy in a series of thirteen patients","volume":"38","author":"Calebotta","year":"1999","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.073_bib50","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1440-0960.1996.tb01013.x","article-title":"Minocycline is a useful adjuvant therapy for pemphigus","volume":"37","author":"Gaspar","year":"1996","journal-title":"Australas J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.02.073_bib51","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1001\/archderm.141.6.699","article-title":"Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris","volume":"141","author":"Heaphy","year":"2005","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.073_bib52","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/archderm.144.1.25","article-title":"Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris","volume":"144","author":"Werth","year":"2008","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.02.073_bib53","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1159\/000448028","article-title":"Efficacy of dapsone in the treatment of pemphigus vulgaris: a single-center case study","volume":"232","author":"Baum","year":"2016","journal-title":"Dermatology"},{"issue":"3 Suppl 1","key":"10.1016\/j.jaad.2021.02.073_bib54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1590\/abd1806-4841.20153408","article-title":"Dapsone in the treatment of pemphigus vulgaris: adverse effects and its importance as a corticosteroid-sparing agent","volume":"90","author":"Quaresma","year":"2015","journal-title":"An Bras Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.02.073_bib55","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/11310740-000000000-00000","article-title":"Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data","volume":"10","author":"G\u00fcrcan","year":"2009","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.073_bib56","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/archderm.140.3.327","article-title":"Pemphigus vulgaris acantholysis ameliorated by cholinergic agonists","volume":"140","author":"Nguyen","year":"2004","journal-title":"Arch Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2021.02.073_bib57","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1001\/archderm.135.10.1275","article-title":"Methotrexate as an adjuvant treatment for\u00a0pemphigus vulgaris","volume":"135","author":"Smith","year":"1999","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.073_bib58","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1365-2133.2009.09246.x","article-title":"Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid","volume":"161","author":"G\u00fcrcan","year":"2009","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.073_bib59","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1684\/ejd.2011.1611","article-title":"Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris","volume":"22","author":"Baum","year":"2012","journal-title":"Eur J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.073_bib60","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/bjd.12474","article-title":"Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients","volume":"169","author":"Tran","year":"2013","journal-title":"Br J Dermatol"},{"issue":"5 Pt 1","key":"10.1016\/j.jaad.2021.02.073_bib61","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0190-9622(08)81506-X","article-title":"The efficacy of combined treatment with prednisone and cyclosporine in patients with pemphigus: preliminary study","volume":"30","author":"Lapidoth","year":"1994","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2021.02.073_bib62","first-page":"1183","article-title":"Cyclosporine for the treatment of pemphigus vulgaris","volume":"28","author":"Luisi","year":"1994","journal-title":"Ann Pharmacother"},{"issue":"2 Pt 1","key":"10.1016\/j.jaad.2021.02.073_bib63","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0190-9622(97)70296-2","article-title":"Long-term remission in selected patients with pemphigus vulgaris treated with cyclosporine","volume":"36","author":"Mobini","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.073_bib64","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000314155","article-title":"Recalcitrant pemphigus vulgaris responding to systemic tacrolimus","volume":"221","author":"B\u00fcsing","year":"2010","journal-title":"Dermatology"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.073_bib65","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3109\/09546634.2013.873763","article-title":"Assessment of the adjuvant effect of tacrolimus in the management of pemphigus vulgaris: a randomized controlled trial","volume":"26","author":"Dastgheib","year":"2015","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.073_bib66","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/jca.21774","article-title":"Safety and efficacy of plasma exchange via direct femoral vein puncture in autoimmune blistering diseases","volume":"35","author":"Yoshida","year":"2020","journal-title":"J Clin Apher"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.073_bib67","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/1744-9987.12557","article-title":"Evaluating the efficacy of double-filtration plasmapheresis in treating five patients with drug-resistant pemphigus","volume":"21","author":"Higashihara","year":"2017","journal-title":"Ther Apher Dial"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.073_bib68","first-page":"E17","article-title":"Plasmapheresis in refractory pemphigus vulgaris: revisiting an old treatment modality used in synchrony with pulse cyclophosphamide","volume":"95","author":"Tay","year":"2015","journal-title":"Cutis"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.073_bib69","doi-asserted-by":"crossref","first-page":"508","DOI":"10.4103\/0378-6323.98092","article-title":"Therapeutic plasma exchange as a crisis option in severe pemphigus vulgaris","volume":"78","author":"Ranugha","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.073_bib70","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2340\/0001555575150152","article-title":"The steroid-sparing effect of long-term plasmapheresis in pemphigus","volume":"75","author":"S\u00f8ndergaard","year":"1995","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2021.02.073_bib71","first-page":"557","article-title":"Severe pemphigus vulgaris: successful combination therapy of plasmapheresis followed by intravenous high-dose immunoglobulin to prevent rebound increase in pathogenic IgG","volume":"18","author":"Aoyama","year":"2008","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2021.02.073_bib72","article-title":"Dapsone, two birds with one stone: a response to \u201cdapsone advantages over trimethoprim-sulfamethoxazole for Pneumocystis pneumonia prophylaxis in immunobullous patients\u201d","author":"Kneiber","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"23","key":"10.1016\/j.jaad.2021.02.073_bib73","doi-asserted-by":"crossref","first-page":"16916","DOI":"10.1074\/jbc.M113.472100","article-title":"Mechanisms of mitochondrial damage in keratinocytes by pemphigus vulgaris antibodies","volume":"288","author":"Kalantari-Dehaghi","year":"2013","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.073_bib74","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.intimp.2015.04.046","article-title":"Pemphigus vulgaris antibodies target the mitochondrial nicotinic acetylcholine receptors that protect keratinocytes from apoptolysis","volume":"29","author":"Chernyavsky","year":"2015","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.073_bib75","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/ijd.14143","volume":"58","author":"Grando","year":"2019","journal-title":"Int J Dermatol"},{"issue":"17","key":"10.1016\/j.jaad.2021.02.073_bib76","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.073_bib77","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1080\/09546634.2018.1484873","article-title":"Rituximab\/IVIG in pemphigus - a 10-year study with a long follow-up","volume":"30","author":"Hamadah","year":"2019","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jaad.2021.02.073_bib78","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.intimp.2016.02.013","article-title":"First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: preliminary retrospective study with a seven year follow-up","volume":"34","author":"Ahmed","year":"2016","journal-title":"Int Immunopharmacol"},{"issue":"27","key":"10.1016\/j.jaad.2021.02.073_bib79","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1056\/NEJMc1508234","article-title":"Long-term remissions in recalcitrant pemphigus vulgaris","volume":"373","author":"Ahmed","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jaad.2021.02.073_bib80","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/j.jaad.2020.04.005","article-title":"Treatment considerations for patients with pemphigus during the COVID-19 pandemic","volume":"82","author":"Shakshouk","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.02.073_bib81","doi-asserted-by":"crossref","first-page":"e14188","DOI":"10.1111\/dth.14188","article-title":"Treatment of pemphigus patients in the COVID-19 era: a specific focus on rituximab","volume":"33","author":"Mahmoudi","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2021.02.073_bib82","first-page":"1","article-title":"Rituximab: a safe therapeutic option during the COVID-19 pandemic?","volume":"1","author":"Di Altobrando","year":"2020","journal-title":"J Dermatol Treat"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.073_bib83","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0738-081X(98)00010-8","article-title":"Drug-induced pemphigus","volume":"16","author":"Brenner","year":"1998","journal-title":"Clin Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.073_bib84","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0738-081X(93)90157-8","article-title":"Drug-induced pemphigus. I. A survey","volume":"11","author":"Brenner","year":"1993","journal-title":"Clin Dermatol"},{"issue":"2 Pt 1","key":"10.1016\/j.jaad.2021.02.073_bib85","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0190-9622(84)70025-9","article-title":"Pemphigus erythematosus. Presentation of four cases and review of literature","volume":"10","author":"Amerian","year":"1984","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.073_bib86","doi-asserted-by":"crossref","DOI":"10.5070\/D3241037928","article-title":"Unusually extensive scalp ulcerations manifested in pemphigus erythematosus","volume":"24","author":"Chandan","year":"2018","journal-title":"Dermatol Online J"},{"issue":"5","key":"10.1016\/j.jaad.2021.02.073_bib87","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1590\/abd1806-4841.20188235","article-title":"Fogo selvagem: endemic pemphigus foliaceus","volume":"93","author":"Hans-Filho","year":"2018","journal-title":"An Bras Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.073_bib88","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.jaad.2013.11.043","article-title":"Pemphigus herpetiformis: from first description until now","volume":"70","author":"Kasperkiewicz","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.02.073_bib89","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/ijd.14395","article-title":"Clinical, pathologic, and immunologic features of pemphigus herpetiformis: a literature review and proposed diagnostic criteria","volume":"58","author":"Costa","year":"2019","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.073_bib90","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1365-4362.1984.tb05688.x","article-title":"Pemphigus vegetans. Neumann type and Hallopeau type","volume":"23","author":"Ahmed","year":"1984","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.073_bib91","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.clindermatol.2015.04.011","article-title":"Pemphigus vegetans of the folds (intertriginous areas)","volume":"33","author":"Ruocco","year":"2015","journal-title":"Clin Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.02.073_bib92","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jaad.2019.11.059","article-title":"IgA pemphigus: a systematic review","volume":"82","author":"Kridin","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.073_bib93","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jaad.2013.09.037","article-title":"IgA pemphigus: case series with emphasis on therapeutic response","volume":"70","author":"Moreno","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"5 suppl","key":"10.1016\/j.jaad.2021.02.073_bib94","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jaad.2006.11.023","article-title":"A novel case of IgA paraneoplastic pemphigus associated with chronic lymphocytic leukemia","volume":"56","author":"Taintor","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.073_bib95","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.det.2011.06.016","article-title":"Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome)","volume":"29","author":"Frew","year":"2011","journal-title":"Dermatol Clin"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.073_bib96","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1087-0024.2004.00832.x","article-title":"Paraneoplastic pemphigus","volume":"9","author":"Anhalt","year":"2004","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.073_bib97","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1365-4632.2009.03995.x","article-title":"Paraneoplastic pemphigus\/paraneoplastic autoimmune multiorgan syndrome","volume":"48","author":"Sehgal","year":"2009","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.073_bib98","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s12032-009-9304-y","article-title":"A critical role of surgery in the treatment for paraneoplastic pemphigus caused by localized Castleman's disease","volume":"27","author":"Fang","year":"2010","journal-title":"Med Oncol"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.073_bib99","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1586\/1744666X.4.3.351","article-title":"Rationale and efficacy for the use of rituximab in paraneoplastic pemphigus","volume":"4","author":"Vezzoli","year":"2008","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"10.1016\/j.jaad.2021.02.073_bib100","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1346-8138.2007.00322.x","article-title":"Paraneoplastic pemphigus","volume":"34","author":"Zhu","year":"2007","journal-title":"J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.02.073_bib101","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2133.1996.tb06349.x","article-title":"Paraneoplastic pemphigus: potential therapeutic effect of plasmapheresis","volume":"134","author":"Izaki","year":"1996","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.073_bib102","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1046\/j.1365-2133.2003.05260.x","article-title":"Topical tacrolimus (FK506) for relapsing erosive stomatitis in paraneoplastic pemphigus","volume":"148","author":"Vecchietti","year":"2003","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.073_bib103","first-page":"105","article-title":"Paraneoplastic pemphigus in two patients with B cell non-Hodgkin's lymphoma: significant responses to cyclophosphamide and prednisolone","volume":"63","author":"Hertzberg","year":"2000","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.jaad.2021.02.073_bib104","first-page":"551","article-title":"Paraneoplastic pemphigus treated with dexamethasone\/cyclophosphamide pulse therapy","volume":"8","author":"Becker","year":"1998","journal-title":"Eur J Dermatol"},{"issue":"5 Pt 1","key":"10.1016\/j.jaad.2021.02.073_bib105","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0190-9622(99)70157-X","article-title":"Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease","volume":"40","author":"Nousari","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.073_bib106","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1046\/j.1365-2133.2000.03365.x","article-title":"Use of mycophenolate mofetil in the treatment of paraneoplastic pemphigus","volume":"142","author":"Williams","year":"2000","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2021.02.073_bib107","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1365-4362.1997.tb01154.x","article-title":"Retroperitoneal round-cell liposarcoma associated with paraneoplastic pemphigus presenting as lichen planus pemphigoides-like eruption","volume":"36","author":"Krunic","year":"1997","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.073_bib108","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/0190-9622(92)70220-A","article-title":"Paraneoplastic pemphigus: a report of three cases including one long-term survivor","volume":"27","author":"Camisa","year":"1992","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.02.073_bib109","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0025-6196(12)61787-X","article-title":"Paraneoplastic pemphigus: a case of prolonged survival","volume":"69","author":"Perniciaro","year":"1994","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.073_bib110","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s12253-008-9133-x","article-title":"Successful immunomodulatory therapy in castleman disease with paraneoplastic pemphigus vulgaris","volume":"15","author":"Miltenyi","year":"2009","journal-title":"Pathol Oncol Res"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.073_bib111","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000070972","article-title":"Successful treatment of B cell chronic lymphocytic leukemia-associated severe paraneoplastic pemphigus with cyclosporin A","volume":"109","author":"Gergely","year":"2003","journal-title":"Acta Haematol"},{"issue":"7","key":"10.1016\/j.jaad.2021.02.073_bib112","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/archderm.1984.01650430127024","article-title":"Adjuvant therapy of pemphigus","volume":"120","author":"Bystryn","year":"1984","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.02.073_bib113","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-4362.1990.tb04765.x","article-title":"Pemphigus therapy with oral prednisolone regimens. A 5-year study","volume":"29","author":"Ratnam","year":"1990","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.073_bib114","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.amjmed.2014.09.003","article-title":"A blistering response: concurrent psoriasis and pemphigus foliaceus","volume":"128","author":"Kurtzman","year":"2015","journal-title":"Am J Med"},{"issue":"9","key":"10.1016\/j.jaad.2021.02.073_bib115","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/ijd.12582","article-title":"Pemphigus herpetiformis: a case series and review of the literature","volume":"54","author":"Laws","year":"2015","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.073_bib116","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1590\/abd1806-4841.20198285","article-title":"Pemphigus vegetans with isolated involvement of the nose and chest: rare variant of pemphigus vulgaris","volume":"94","author":"Feitoza","year":"2019","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.jaad.2021.02.073_bib117","series-title":"Comprehensive Dermatologic Drug Therapy E-Book","author":"Wolverton","year":"2019"},{"key":"10.1016\/j.jaad.2021.02.073_bib118","article-title":"Rituximab treatment of pemphigus foliaceus- a retrospective study of 12 patients","author":"Palacios-Alvarez","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2021.02.073_bib119","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1365-4632.2008.03682.x","article-title":"Treatment of refractory pemphigus erythematosus with rituximab","volume":"47","author":"Diab","year":"2008","journal-title":"Int J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2021.02.073_bib120","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/j.1365-4632.2003.01478.x","article-title":"Mild pemphigus foliaceus responding to combination therapy with niacinamide and tetracycline","volume":"42","author":"Chen","year":"2003","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.02.073_bib121","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0190-9622(08)80651-2","article-title":"Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases","volume":"28","author":"Chaffins","year":"1993","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2021.02.073_bib122","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/jid.2010.91","article-title":"Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial","volume":"130","author":"Beissert","year":"2010","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.02.073_bib123","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/CM9.0000000000000671","article-title":"Acute generalized exanthematous pustulosis induced by mycophenolate mofetil: a case complicated with pemphigus foliaceus","volume":"133","author":"Chen","year":"2020","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"10.1016\/j.jaad.2021.02.073_bib124","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/120347541201600512","article-title":"Pemphigus vegetans associated with intranasal cocaine abuse","volume":"16","author":"Ngo","year":"2012","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.073_bib125","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/archderm.1969.01610250076018","article-title":"Treatment of pemphigus vulgaris with methotrexate","volume":"100","author":"Lever","year":"1969","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.02.073_bib126","doi-asserted-by":"crossref","first-page":"e13801","DOI":"10.1111\/dth.13801","article-title":"Successful treatment of pemphigus foliaceous and ankylosing spondylitis with infliximab and methotrexate: a case report","volume":"33","author":"Kaya Erdogan","year":"2020","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.jaad.2021.02.073_bib127","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1525-1470.2012.01746.x","article-title":"A case of pemphigus herpetiformis occurring in a 9-year-old boy","volume":"30","author":"Leithauser","year":"2013","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.02.073_bib128","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2133.2009.09034.x","article-title":"An \u201cn-of-1\u201d placebo-controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris","volume":"160","author":"Arnold","year":"2009","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.02.073_bib129","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/ced.14141","article-title":"Verrucous variant of pemphigus foliaceus","volume":"45","author":"Ohashi","year":"2020","journal-title":"Clin Exp Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2021.02.073_bib130","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1365-4632.2007.03225.x","article-title":"Paraneoplastic pemphigus in association with B cell lymphocytic leukemia and hepatitis C: favorable response to intravenous immunoglobulins and prednisolone","volume":"46","author":"Nanda","year":"2007","journal-title":"Int J Dermatol"},{"issue":"15","key":"10.1016\/j.jaad.2021.02.073_bib131","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s40265-018-0976-5","article-title":"Targeted therapies for autoimmune bullous diseases: current status","volume":"78","author":"Amber","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jaad.2021.02.073_bib132","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.atherosclerosissup.2017.05.044","article-title":"Successful and well-tolerated bi-weekly immunoadsorption regimen in pemphigus vulgaris","volume":"30","author":"Dietze","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.jaad.2021.02.073_bib133","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3389\/fimmu.2018.01935","article-title":"Immunoadsorption of desmoglein-3-specific IgG abolishes the blister-inducing capacity of pemphigus vulgaris IgG in neonatal mice","volume":"9","author":"Hofrichter","year":"2018","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jaad.2021.02.073_bib134","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/ced.12073","article-title":"Evaluation of cyclophosphamide pulse therapy as an adjuvant to oral corticosteroid in the management of pemphigus vulgaris","volume":"38","author":"Sharma","year":"2013","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.073_bib135","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1067\/S0190-9622(03)00859-4","article-title":"Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus","volume":"49","author":"Cummins","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.02.073_bib136","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.4103\/njcp.njcp_87_18","article-title":"Pemphigus vegetans presenting as serpiginous oral, esophageal and genital mucosal ulcers undiagnosed for 3 years","volume":"21","author":"Hadlaq","year":"2018","journal-title":"Niger J Clin Pract"},{"issue":"11","key":"10.1016\/j.jaad.2021.02.073_bib137","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1365-4362.1994.tb01003.x","article-title":"Treatment of oral pemphigus vulgaris","volume":"33","author":"Chrysomallis","year":"1994","journal-title":"Int J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2021.02.073_bib138","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1365-4362.1991.tb04361.x","article-title":"The role of cyclosporine A in the treatment of pemphigus erythematosus","volume":"30","author":"Campolmi","year":"1991","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.073_bib139","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1346-8138.1998.tb02379.x","article-title":"Pemphigus vegetans involving the esophagus","volume":"25","author":"Ichimiya","year":"1998","journal-title":"J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.02.073_bib140","doi-asserted-by":"crossref","first-page":"495","DOI":"10.4103\/0019-5154.103074","article-title":"Pemphigus foliaceus masquerading as IgA pemphigus and responding to dapsone","volume":"57","author":"Chatterjee","year":"2012","journal-title":"Indian J Dermatol"},{"issue":"suppl 3","key":"10.1016\/j.jaad.2021.02.073_bib141","doi-asserted-by":"crossref","first-page":"S310","DOI":"10.5021\/ad.2011.23.S3.S310","article-title":"The Neumann type of pemphigus vegetans treated with combination of dapsone and steroid","volume":"23","author":"Son","year":"2011","journal-title":"Ann Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.073_bib142","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1001\/archdermatol.2010.409","article-title":"A pilot study of etanercept treatment for pemphigus vulgaris","volume":"147","author":"Fiorentino","year":"2011","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.02.073_bib143","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jaad.2006.08.041","article-title":"Pemphigus foliaceus treated with etanercept","volume":"55","author":"Gubinelli","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.073_bib144","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/bjd.13350","article-title":"A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone","volume":"172","author":"Hall","year":"2015","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.02.073_bib145","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2133.2009.09208.x","article-title":"The use of sulfasalazine and pentoxifylline (low-cost antitumour necrosis factor drugs) as adjuvant therapy for the treatment of pemphigus vulgaris: a comparative study","volume":"161","author":"el-Darouti","year":"2009","journal-title":"Br J Dermatol"},{"issue":"6544","key":"10.1016\/j.jaad.2021.02.073_bib146","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/bmj.293.6544.420","article-title":"Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years","volume":"293","author":"Amos","year":"1986","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"11","key":"10.1016\/j.jaad.2021.02.073_bib147","first-page":"976","article-title":"The efficacy of acyclovir in treatment of the pemphigus vulgaris","volume":"18","author":"Iraji","year":"2013","journal-title":"J Res Med Sci"},{"issue":"3","key":"10.1016\/j.jaad.2021.02.073_bib148","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1600-0609.2004.00280.x","article-title":"Alemtuzumab-induced remission of both severe paraneoplastic pemphigus and leukaemic bone marrow infiltration in a case of treatment-resistant B cell chronic lymphocytic leukaemia","volume":"73","author":"Hohwy","year":"2004","journal-title":"Eur J Haematol"},{"issue":"8","key":"10.1016\/j.jaad.2021.02.073_bib149","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1111\/j.1365-2230.2009.03472.x","article-title":"Necrotizing fasciitis caused by Cryptococcus neoformans in a patient with pemphigus vegetans","volume":"34","author":"Adachi","year":"2009","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.073_bib150","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2133.1982.tb00909.x","article-title":"Plasma exchange in corticosteroid-resistant pemphigus","volume":"106","author":"Roujeau","year":"1982","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.073_bib151","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1468-3083.2010.03703.x","article-title":"The role of therapeutic plasma exchange in pemphigus vulgaris","volume":"25","author":"Sagi","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2021.02.073_bib152","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1473-0502(02)00095-2","article-title":"Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid","volume":"28","author":"Mazzi","year":"2003","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jaad.2021.02.073_bib153","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3389\/fimmu.2019.00978","article-title":"Current clinical trials in pemphigus and pemphigoid","volume":"10","author":"Izumi","year":"2019","journal-title":"Front Immunol"}],"updated-by":[{"DOI":"10.1016\/j.jaad.2021.06.005","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000}}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221004734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221004734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,25]],"date-time":"2024-08-25T09:22:50Z","timestamp":1724577770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962221004734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":153,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0190962221004734"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2021.02.073","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intraepithelial autoimmune bullous dermatoses disease activity assessment and therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2021.02.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(21)00789-1","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}